1.The Role of I-131 MIBG cardiac scintigraphy in diagnosing dementia with lewy bodies : A case report
Matthew Stephen L. Jatic ; Eduardo Erasto S. Ongkeko
The Philippine Journal of Nuclear Medicine 2021;16(1):26-35
The objective of this case report is to highlight the role of Iodine-131 metaiodobenzylguanidine (MIBG) cardiac
scintigraphy in discriminating Dementia with Lewy Bodies (DLB) from other neurodegenerative diseases such as
Alzheimer’s Disease. This patient is a known case of Parkinson’s disease and has been treated as such since
2011. However, the patient also concurrently deals with visual hallucinations and because of this, the patient’s
attending neurologist wanted to rule in the diagnosis of DLB rather than AD. Hence, an I-131 MIBG cardiac scan
was requested in order to support the diagnosis of DLB. The use of I-131 MIBG cardiac scintigraphy as a
diagnostic tool for diagnosing Lewy Body Dementia is not prevalent and to our knowledge, this was the first
time in the country that this procedure was done (December 9, 2019).
3-Iodobenzylguanidine
;
Lewy Body Disease
;
Radionuclide Imaging
3.Improvement of Visuo-spatial Function Assessed by Raven’s Colored Progressive Matrices in Dementia with Lewy Bodies by Donepezil Treatment.
Yuta YOSHINO ; Takaaki MORI ; Taku YOSHIDA ; Yasutaka TOYOTA ; Hideaki SHIMIZU ; Jun Ichi IGA ; Shusaku NISHITANI ; Shu Ichi UENO
Clinical Psychopharmacology and Neuroscience 2017;15(3):243-247
OBJECTIVE: Donepezil is used to improve cognitive impairment of dementia with Lewy bodies (DLB). Visuo-spatial dysfunction is a well-known symptom of DLB. Non-verbal Raven’s Colored Progressive Matrices (RCPM) were used to assess both visual perception and reasoning ability in DLB subjects treated with donepezil. METHODS: Twenty-one DLB patients (mean age, 78.7±4.5 years) were enrolled. RCPM assessment was performed at the time of starting donepezil and within one year after starting donepezil. RESULTS: There were significant improvements of RCPM in the total scores between one year donepezil treatment (p=0.013), in both Set A score (p=0.002) and Set AB score (p=0.015), but trend in the Set B score (p=0.083). CONCLUSION: Donepezil is useful for improving visuo-spatial impairment in DLB, but not for problem-solving impairment.
Cholinesterase Inhibitors
;
Cognition Disorders
;
Dementia*
;
Humans
;
Lewy Bodies*
;
Lewy Body Disease
;
Spatial Processing
;
Visual Perception
4.A Case of Probable Diffuse Lewy Body Dementia.
Jin Sook CHEON ; Hancheol YOON
Journal of Korean Geriatric Psychiatry 2000;4(2):199-206
A case of Lewy body dementia in a 71 year-old male patient was reported and related articles were also reviewed. He has been ill with Parkinsonism since 1988, and referred to the neuropsychiatrist because of depression since 1989. Episodically he has experienced dizziness, falls and low blood pressure. Mild cognitive decline including memory, attention, language, and visuospatial ability accompanied by occasional fluctuation of consciousness, confusion, visual hallucination and disorientation was developed on February 9th in 2000. Such symptoms were repeated thereafter, and responded on donepezil in addition to the antiparkinsonian drugs.
Aged
;
Consciousness
;
Depression
;
Dizziness
;
Hallucinations
;
Humans
;
Hypotension
;
Lewy Bodies*
;
Lewy Body Disease*
;
Male
;
Memory
;
Parkinsonian Disorders
5.The clinical value of 123I-metaiodobenzylguanidine myocardial imaging in the diagnosis of dementia with Lewy bodies.
Weiting LIU ; Xilan YAO ; Xiaohong OU
Journal of Biomedical Engineering 2023;40(3):595-601
Metaiodobenzylguanidine (MIBG) is an analog of norepinephrine that accumulates in sympathetic nerve endings soon after intravenous administration. The degree of accumulation reflects the uptake, storage and release of transmitters by noradrenergic neurons. Myocardial imaging with 123I labeled MIBG ( 123I-MIBG) can be used to estimate the extent of local myocardial sympathetic nerve damage, which has been widely used in the diagnosis and treatment of various heart diseases. In recent years, numerous studies have been carried out on the application of 123I-MIBG in the diagnosis of degenerative diseases of the nervous system (such as Parkinson's disease and dementia of Lewy body), and have made some achievements. The purpose of this review is to summarize the current clinical application of 123I-MIBG myocardial imaging in the diagnosis of dementia with Lewy bodies, the problems in imaging technology and the possible research directions in the future, so as to provide valuable reference information for clinicians to reasonably and accurately apply this technology in the early diagnosis and discrimination of dementia.
Humans
;
Lewy Bodies
;
3-Iodobenzylguanidine
;
Lewy Body Disease/diagnostic imaging*
;
Iodine Radioisotopes
6.¹²³I-Meta-iodobenzylguanidine Sympathetic Imaging: Standardization and Application to Neurological Diseases
Kenichi NAKAJIMA ; Masahito YAMADA
Chonnam Medical Journal 2016;52(3):145-150
¹²³I-meta-iodobenzylguanidine (MIBG) has become widely applied in Japan since its introduction to clinical cardiology and neurology practice in the 1990s. Neurological studies found decreased cardiac uptake of ¹²³I-MIBG in Lewy-body diseases including Parkinson's disease and dementia with Lewy bodies. Thus, cardiac MIBG uptake is now considered a biomarker of Lewy body diseases. Although scintigraphic images of ¹²³I-MIBG can be visually interpreted, an average count ratio of heart-to-mediastinum (H/M) has commonly served as a semi-quantitative marker of sympathetic activity. Since H/M ratios significantly vary according to acquisition and processing conditions, quality control should be appropriate, and quantitation should be standardized. The threshold H/M ratio for differentiating Lewy-body disease is 2.0-2.1, and was based on standardized H/M ratios to comparable values of medium-energy collimators. Parkinson's disease can be separated from various types of parkinsonian syndromes using cardiac ¹²³I-MIBG, whereas activity is decreased on images of Lewy-body diseases using both ¹²³I-ioflupane for the striatum and ¹²³I-MIBG. Despite being a simple index, the H/M ratio of ¹²³I-MIBG uptake is reproducible and can serve as an effective tool to support a diagnosis of Lewy-body diseases in neurological practice.
3-Iodobenzylguanidine
;
Cardiology
;
Dementia
;
Diagnosis
;
Japan
;
Lewy Bodies
;
Lewy Body Disease
;
Neurology
;
Nuclear Medicine
;
Parkinson Disease
;
Parkinsonian Disorders
;
Quality Control
7.Papillary Meningioma Presenting as Rapidly Progressive Dementia and Parkinsonism.
In Seok PARK ; Seung Hee NA ; Young Do KIM ; In Uk SONG ; Lee So MAENG ; Youngsoon YANG
Dementia and Neurocognitive Disorders 2013;12(3):81-85
There are a variety of different causes of parkinsonism including PD, secondary parkinsonism, and the parkinsonism plus syndromes. Secondary parkinsonism is caused by structural, toxic, metabolic, or infectious mechanisms. Among structural causes, intracranial neoplasms are a rare cause of secondary parkinsonism. Moreover, there are almost never case reports with intracranial space-occupying lesions resulting in parkinsonism associated with rapid cognitive impairment. Therefore, we report herein a 37-year-old woman diagnosed with papillary meningioma who presented with parkinsonism associated with rapidly progressive cognitive impairment mimicking diffuse Lewy body disease.
Adult
;
Brain Neoplasms
;
Dementia
;
Female
;
Humans
;
Lewy Body Disease
;
Meningioma
;
Parkinson Disease, Secondary
;
Parkinsonian Disorders
8.Pathological Changes to the Subcortical Visual System and its Relationship to Visual Hallucinations in Dementia with Lewy Bodies.
Daniel ERSKINE ; John-Paul TAYLOR ; Alan THOMAS ; Daniel COLLERTON ; Ian MCKEITH ; Ahmad KHUNDAKAR ; Johannes ATTEMS ; Christopher MORRIS
Neuroscience Bulletin 2019;35(2):295-300
Dementia
;
pathology
;
Hallucinations
;
pathology
;
Humans
;
Lewy Body Disease
;
pathology
;
Nerve Net
;
pathology
9.Clinical Features of Other Dementias.
Journal of Korean Geriatric Psychiatry 2000;4(1):58-71
Dementias can be calssified into cortical, subcortical, cortical-subcortical and multifocal ones based on the major pathological distribution within the brain. The literatures of recent knowledge about clinical features of other dementias than Alzheimer's and vascular ones, which were most frequently experienced by many clinicians were reviewed. That is, cortical dementias such as Pick's disease, frontal lobe type dementia and non-Alzheimer's type lobar atrophy including fronto-temporal dementia, progressive dysphasia, fronto-temporal dementia with motor neuron disease, and alcohol-related dementia were reviewed. Subcortical dementias such as dementias accompanying Parkinson's disease, Huntington's disease and progressive supranuclear palsy, and cortical-subcortical dementias such as Lewy body dementiaq and cortical-basal degeneration were also reviewed. As multifocal dementias, prion dementias including KUru, Creutzfeldt-Jakob disease, fatal familial insomnia and Gerstmann-Strussler-Sheinker syndrone, and AIDS dementia were also reviewed.
Aphasia
;
Atrophy
;
Brain
;
Creutzfeldt-Jakob Syndrome
;
Dementia*
;
Frontal Lobe
;
Frontotemporal Dementia
;
Huntington Disease
;
Insomnia, Fatal Familial
;
Kuru
;
Lewy Bodies
;
Lewy Body Disease
;
Motor Neuron Disease
;
Parkinson Disease
;
Pick Disease of the Brain
;
Supranuclear Palsy, Progressive
10.Psychosis in Dementia.
Jin Yeong KIM ; Seong Hoon JEONG ; In Won CHUNG
Journal of Korean Geriatric Psychiatry 2009;13(1):3-10
Psychosis in patients with dementia contributes substantially to patient morbidity and caregiver distress. The concept of psychosis of Alzheimer's disease (AD) and other types of dementia is developed with respect to prevalence, incidence, clinical characteristics, clinical course, and potential response to treatment. This article provides an overview of concept of psychosis in dementia. Published prevalence estimates of psychosis in patients with AD range from 10 to 73% within clinical populations. There is a continuing persistence of psychotic symptomatology among people with AD;most patients with psychosis continue to fulfill criteria for psychosis of dementia over at least 3 months, and over a half may have psychotic symptoms persist over a year. Among people with AD who have no psychotic symptoms there appears to be an annualized incidence of psychosis of about 20% in outpatients, and a much higher rate in nursing home patients. Frontal hypometabolism and greater frontal neuropsycological deficits occur in AD patients with psychosis in comparison to those without. There is some evidence that psychotic symptoms improve modestly with antipsychotic medication treatment, although optimal treatment guidelines have been elusive. The characteristics of psychosis in Parkinson's disease, Lewy body dementia, frontotemporal dementia and vascular dementia were also reviewed. Conclusively, further research to support the validity of a syndrome of psychosis in various types of dementia, as well as AD is needed.
Alzheimer Disease
;
Caregivers
;
Dementia
;
Dementia, Vascular
;
Frontotemporal Dementia
;
Humans
;
Incidence
;
Lewy Body Disease
;
Nursing Homes
;
Outpatients
;
Parkinson Disease
;
Prevalence
;
Psychotic Disorders